REBAMIPIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H15ClN2O4
Molecular Weight	370.786
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3

InChI

InChIKey=ALLWOAVDORUJLA-UHFFFAOYSA-N

InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9753220
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/rebamipide.html | http://www.mims.com/philippines/drug/info/rebamipide?mtype=generic | https://www.ncbi.nlm.nih.gov/pubmed/27098506

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2. Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China, and India (where it is marketed under the trade name Rebagen). It is not approved by the Food and Drug Administration for use in the United States. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
AMP-activated protein kinase, AMPK 17 Target ID: CHEMBL2096907 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28011266	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Peptic ulcer 72 Sources: http://www.mims.com/philippines/drug/info/rebamipide?mtype=generic	Primary	Approved 8583	Mucosta Approved Use Unknown
Gastritis 46 Sources: http://www.mims.com/philippines/drug/info/rebamipide?mtype=generic	Primary	Approved 8583	Mucosta Approved Use Unknown
Gastropathy 2 Sources: https://clinicaltrials.gov/ct2/show/NCT00641004	Primary	Phase IV 63	Mucosta Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.96 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.79 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.18 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.66 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.13 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.39 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.19 ng/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
218.12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110013/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	REBAMIPIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5.45 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.71 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.55 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.3 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.48 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
851.68 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110013/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	REBAMIPIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
10.26 h OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.64 h OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.34 h OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.19 h OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.64 h OTHER GOV'T https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 \| https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered:	REBAMIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.96 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110013/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	REBAMIPIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.4% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/180078_1319760Q1029_1_006_1F.pdf#page=31			REBAMIPIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11564000/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11564000/	Sources: https://pubmed.ncbi.nlm.nih.gov/11564000/
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/	Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness (grade 1, 0.44%) Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/	Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/

AEs

AE	Significance	Dose	Population
Dizziness	grade 1, 0.44% Disc. AE	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33827990/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 activator 150 substrate 1946 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B3 961 CYP2A6 879 OATP1B1 1079 CYP19A1 429 CYP1A2 2153 CYP2C19 2057 CYP2E1 1060	MRP 9 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14738594/	no [IC50 6800 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	no [Inhibition 50 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	no [Inhibition 50 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	no [Inhibition 50 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	no [Inhibition 50 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	no [Inhibition 50 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5042#section=BioAssay-Results Page: 90.0	no
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5042#section=BioAssay-Results Page: 7.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5042#section=BioAssay-Results Page: 128.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5042#section=BioAssay-Results Page: 149.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2OTc3NzEifX0=	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2OTc3NzEifX0=	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27557477/	no
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12162853/	yes [Km 1010 uM]
MRP 9	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27557477/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27557477/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5042#section=BioAssay-Results Page: 40.0

PubMed

Title	Date	PubMed
Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers.	2007-08	17410467
[Safe improvement of drug absorption by combinatorial use of sodium laurate with amino acids: cytoprotection by amino acids and its mechanisms].	2007-04	17409688
Rebamipide contributes to reducing adverse effects of long-term administration of omeprazole in rats.	2007-04	17342392
Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis.	2007-02	17295881
Ileal cancer and erosions in the small intestine revealed by capsule endoscopy.	2007-02	17285495
Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice.	2007-01	17186389
Rebamipide inhibits gastric cancer cell growth.	2007-01	17171453
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).	2006-12	17287897
Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan.	2006-12	17074021
Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption.	2006-10-10	16973235
[Case of drug-induced lung injury due to Rebamipide].	2006-10	17087338
Ambroxol for the prevention of acute upper respiratory disease.	2006-06	16820995
OPC-12759 increases proliferation of cultured rat conjunctival goblet cells.	2006-06	16783146
Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids.	2006-03-10	16410031
The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production.	2006-03	16039106
Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide.	2006-02	16462041
Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: a case report.	2006-01-28	16489687
A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide.	2006-01	16706820
Oxidative stress involvement and gene expression in indomethacin-induced gastropathy.	2006	17207306
Therapeutic effect of DA-9601 on chronic reflux gastritis induced by sodium taurocholate in rats.	2005-12-21	16437712
Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report.	2005-12	16416182
Radical scavengers: a remedy for presbyacusis. A pilot study.	2005-12	16303676
[Quality of ulcer healing and rebamipide].	2005-11	16363567
Prevention by rebamipide of acute reflux esophagitis in rats.	2005-10	16184428
Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils.	2005-10	16184427
Rebamipide reduces indomethacin-induced gastric injury in mice via down-regulation of ICAM-1 expression.	2005-10	16184426
Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells.	2005-10	16184425
Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells.	2005-10	16184424
Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice.	2005-10	16184423
Rebamipide decreases the susceptibility of gastric mucosa to acid-induced injury in rats by inhibiting neutrophil activation.	2005-10	16184422
15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.	2005-10	16184418
Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.	2005-10	16184415
Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.	2005-10	16184413
Direct autoradiographic evidence that rebamipide interacts with neutrophils in dextran sulfate sodium induced colitis in rats.	2005-10	16184412
Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression.	2005-10	16184411
Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.	2005-08-19	15993841
COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice.	2005-08	16170898
NADPH oxidase mediates interleukin-6 expression in cerulein-stimulated pancreatic acinar cells.	2005-07	15833277
[Enema therapy for ulcerative colitis patients].	2005-05	15881180
Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells.	2004-11-28	15556137
Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine.	2004-09-14	15342181
Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats.	2004-09	15521332
Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model.	2004-08	15257002
Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product.	2004-05	15293556
Preventive effect of the flavonoid, wogonin, against ethanol-induced gastric mucosal damage in rats.	2004-03	15139485
Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?	2004-02	15104358
Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis.	2004	15687726
Study of inhibition of CYP2A6 by some drugs derived from quinoline.	2003-12	14738594
[Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].	2003-11	14672045
Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers.	2003	17536891

Patents

Sample Use Guides

In Vivo Use Guide

100 mg tid, in the morning, evening and before bedtime.

Route of Administration: Oral

In Vitro Use Guide

Human gastric carcinoma AGS cells were treated with rebamipide at 0.1-5mkM for 2 h. Cells were lysed followed by western blot analysis. The blots were probed with an anti-p-AMPKalpha antibody specific for threonine 172-phosphorylated AMPKalpha.

Name

Type

Language

REBAMIPIDE

Official Name

English

MUCOSTA

Preferred Name

English

REBAMIPIDE [MI]

Common Name

English

REBATOR

Brand Name

English

(±)-.ALPHA.-(P-CHLOROBENZAMIDO)-1,2-DIHYDRO-2-OXO-4-QUINOLINEPROPIONIC ACID

Common Name

English

NSC-758955

Code

English

PROAMIPIDE

Brand Name

English

4-QUINOLINEPROPANOIC ACID, .ALPHA.-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-

Systematic Name

English

rebamipide [INN]

Common Name

English

REBAMIPIDE [JAN]

Common Name

English

OPC-12759

Code

English

Rebamipide [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A02BX14